SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.

  title={SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.},
  author={Yury Vald{\'e}s-Balb{\'i}n and Darielys Santana-Mederos and Lauren Quintero and Sonsire Fern{\'a}ndez and Laura M Rodr{\'i}guez and Belinda S{\'a}nchez Ram{\'i}rez and Rocmira Perez-Nicado and Claudia Acosta and Yanira M{\'e}ndez and Manuel G. Ricardo and Tays Hern{\'a}ndez and Gretchen Bergado and Franciscary Pi and Annet Valdes and Tania Carmenate and Ubel Ram{\'i}rez and Reinaldo Oliva and Jean Pierre Soubal and Raine Garrido and Félix Cardoso and Mario Landys and Humberto Gonz{\'a}lez and Mildrey Fari{\~n}as and Juliet Enriquez and Enrique Noa and Anamary Suarez and Cheng Fang and Luis Ariel Espinosa and Yassel Ramos and Luis Javier Gonz{\'a}lez and Yanet Climent and Gertrudis Rojas and Ernesto Relova-Hern{\'a}ndez and Yanelys Cabrera Infante and Sum Lai Losada and Tammy Boggiano and Eduardo Ojito and Kalet Leon and Fabrizio Chiodo and Françoise Paquet and Guang-Wu Chen and Daniel G. Rivera and Dagmar Garc{\'i}a-Rivera and Vicente Verez Bencomo},
  journal={ACS chemical biology},
Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines at an unprecedented pace. Vaccines approved for use and those in development intend to elicit neutralizing antibodies to block viral sites binding to the host's cellular receptors. Virus infection is mediated by the spike glycoprotein trimer on the virion surface via its receptor binding domain (RBD). Antibody response to this domain is an important outcome of immunization and correlates… 
7 Citations
Murine monoclonal antibodies against RBD of the SARS-CoV-2 spike protein as useful analytical tools for subunit vaccine development and clinical trials
Nine murine MAbs against the RBD of the SARS-CoV-2 spike protein were obtained by hybridoma technology and characterization of purified antibodies demonstrated that five of them have affinities in the order of 108 L/mol, suitable for the development of a sandwich ELISA to quantitate RBD-S recombinant antigens in biomanufacturing processes.
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
The prevalence and biological structure of these variants and the efficacy of currently used vaccines against the SARS-CoV-2 variants are summarized to provide guidance on how to design vaccines more rationally against the variants.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme
SOBERANA 02 was safe and immunogenic in persons aged 19–80 years, eliciting neutralizing antibodies and specific T cell response and it was higher after both the homologous and heterologous third doses; theheterologous scheme showing a higher immunological response.
Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
Two doses of SOBERANA 02 were well tolerated, safe an immunogenic in adults aged 19-80 years old, and the heterologous combination with a third dose of SobERANA Plus increased neutralizing antibodies, detectable 7-8 months after the third dose.
COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations
This review aims to evaluate the existing evidence of COVID-19 vaccinations on special populations and to provide clues to guide vaccination decision making to balance the benefits and risks of vaccinations.
In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 in a single ESI–MS spectrum
In this work, several recombinant RBD proteins produced in five expression systems were characterized using a non-conventional protocol known as in-solution buffer-free digestion (BFD), and it is foresee that it can be also helpful to the characterization of mutated RBDs.
Nano-chemistry and Bio-conjugation with perspectives on the design of Nano-Immune platforms, vaccines and new combinatorial treatments
This Mini-Review and Opinion letter, it was addressed different themes and topics implicated in the development of new treatments and vaccines applied to pathologies developed in humans such as by


A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
It is shown that a recombinant vaccine that comprises residues 319–545 of the RBD of the spike protein induces a potent functional antibody response in immunized mice, rabbits and non-human primates as early as 7 or 14 days after the injection of a single vaccine dose.
Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines
This review summarizes with a critical view the molecular aspects associated with the interaction of SARS-CoV-2 RBD with its receptor in human cells, the angiotensin-converting enzyme 2 (ACE2), the epitopes involved in the neutralizing activity, and the impact of virus mutations thereof.
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
The data suggests that RBD-SpyVLP provides strong potential to address clinical and logistic challenges of the COVID-19 pandemic, and is thermostable and can be lyophilised without losing immunogenicity, to facilitate global distribution and reduce cold-chain dependence.
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
A role for potent neutralizing antibodies (nAbs) in prophylaxis, and potentially therapy, of COVID-19 is suggested, as indicated by maintained weight and low lung viral titers in treated animals, and the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters.
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
RBD- and HR-based nanoparticles present a promising vaccination approach against SARS-CoV-2 and other coronaviruses.
Structural basis of a shared antibody response to SARS-CoV-2
It is found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein, which is promising for vaccine design.
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
The authors generate a capsid-like particle based vaccine candidate displaying the receptor-binding domain of the SARS-CoV-2 spike protein and show induction of neutralizing antibodies after intramuscular prime-boost immunization in mice.
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
A blocking assay based on the recombinant receptor-binding domain of SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2 receptor provides an alternative to conventional antibody neutralization assays requiring live virus.
Potently neutralizing and protective human antibodies against SARS-CoV-2
An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.
Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic
The study highlights the critical role of the immunogenicity of the RBD domain upon SARS-CoV-2 infection and the alternate vaccine designs that could serve as effective prophylactics against the pandemic.